Moody's affirms J&J's (JNJ) Aaa rating; raises outlook from Negative to Stable
Moody's affirms J&J's (NYSE: JNJ) Aaa rating; raises outlook from Negative to Stable
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ): Notes From Management Meetings - UBS
- FDA Approves STELARA® (ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn's Disease
- Janssen Announces FDA Approval of STELARA as Crohn's Disease Treatment
Create E-mail Alert Related CategoriesCredit Ratings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!